Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium
- 1 February 2025
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 46 (2)
Abstract
Lung cancer is the leading cause of cancer mortality. To investigate genetic determinants for prognosis among patients diagnosed with early-stage non-small cell lung cancer (NSCLC), we conducted the first large-scale genome-wide association prognostic study using data from the International Lung Cancer Consortium (ILCCO) through a two-phase analysis. Phase 1 includes the discovery of genome-wide association studies analysis using a multivariable Cox PH model on 3428 NSCLC patients of European ancestry from 10 ILCCO participating studies to identify genetic variants associated with overall survival and validation analysis for genome-wide significant variants (P-value ≤5 × 10−8) using the Cancer Genome Atlas (TCGA). Phase 2 aims to identify causal variants using functional analyses of genome-wide significant and suggestive variants (P-value ≤1 × 10−5), including variant-epigenetic functional annotation (FAVOR), CHIP-seq data, variant-gene expression association, and colocalization analysis. We identified two significant variants; of those, a locus at 9q21.31 (rs117979484) was significant at the genome-wide level (P = 3.67 × 10−8) and validated in TCGA (P = 0.03). Three suggestive variants were found to have a putative epigenetic function: intronic variants rs149281784 (BCL7B gene) and rs148031766 (POM121 gene) both located at 7q11.23 and in moderate linkage disequilibrium with each other; and variant rs2471630 (SRCIN1 gene; 17q12). Specifically, variants rs149281784 and rs148031766 have potential regulatory roles in the transcriptional activation of the BCL7B gene and POM121 gene. Exploratory survival analyses in the squamous cell carcinomas subgroup also identified a significant variant, rs138467404 (GRHL-2 gene; 8q22.3) at a genome-wide level (P = 4.75 × 10−8) and validated by TCGA (P = 0.02). These new findings indicate potential novel pathways associated with early-stage NSCLC prognosis. Future research may validate additional genome-wide suggestive variants as being relevant for lung cancer outcomes.Keywords
Funding Information
- Alan B. Brown Chair
- The Posluns Family Fund
- The Lusi Wong Fund
- Princess Margaret Cancer Foundation
- CARET Beta Carotene and Retinol Efficacy Trial
- National Cancer Institute
- National Institutes of Health (U01-CA063673)
- National Institutes of Health (UM1-CA167462)
- National Institutes of Health (U01-CA167462)
- National Institutes of Health (U19 CA203654)
- Fred Hutchinson Cancer Center (U01-CA209414)
- Fred Hutchinson Cancer Center (P30000002)
- Roy Castle Lung Cancer Foundation
- Moffitt's Cancer Center (P30-CA076292)
- Sheffield Hospitals Charity
- Weston Park Hospital Cancer Charity
- Intramural Research Program, Division of Cancer Epidemiology and Genetics
This publication has 49 references indexed in Scilit:
- Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer ConsortiumJournal of Thoracic Oncology, 2022
- Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the USJAMA Oncology, 2021
- New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapyGeneral Hospital Psychiatry, 2019
- Serum MicroRNA‐150 Predicts Prognosis for Early‐Stage Non‐Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1Clinical Pharmacology & Therapeutics, 2017
- A reference panel of 64,976 haplotypes for genotype imputationNature Genetics, 2016
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherinBiochemical and Biophysical Research Communications, 2014
- Grainyhead-like 2 regulates neural tube closure and adhesion molecule expression during neural fold fusionDevelopmental Biology, 2011
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Molecular Interaction between TLE1 and the Carboxyl-Terminal Domain of HES-1 Containing the WRPW MotifBiochemical and Biophysical Research Communications, 1996